| EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified studied in …STUDIED_INderived10 of 20show all (up to 200) |
|---|
| → studied in | NCT04231877Phase 1 · active not recruiting Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 20 trials mapped (13 active) | — | — | EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03984448Phase 2/Phase 3 · active not recruiting Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas · condition mapped ONTOLOGY_EXACT · 20 trials mapped (13 active) | — | — | EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04799275Phase 2/Phase 3 · active not recruiting Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 20 trials mapped (13 active) | — | — | EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03038672Phase 2 · active not recruiting Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas · condition mapped ONTOLOGY_EXACT · 20 trials mapped (13 active) | — | — | EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07097363Phase 2 · recruiting Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 20 trials mapped (13 active) | — | — | EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05507541Phase 2 · active not recruiting TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 20 trials mapped (13 active) | — | — | EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06544265Phase 1 · recruiting SynKIR-310 for Relapsed/Refractory B-NHL · condition mapped ALIAS · 20 trials mapped (13 active) | — | — | EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05934448Phase 2 · recruiting Pembro Plus CAR T-cell Therapy in R/R in PMBCL · condition mapped ALIAS · 20 trials mapped (13 active) | — | — | EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05544019Phase 1 · recruiting Study of SGR-1505 in Mature B-Cell Neoplasms · condition mapped ALIAS · 20 trials mapped (13 active) | — | — | EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05583149Phase 2 · active not recruiting Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas · condition mapped ALIAS · 20 trials mapped (13 active) | — | — | EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | 1 | Observed | clinicaltrials | graph → |